Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research aims to improve the Health Related Quality of Life HRQOL for women with metastatic breast cancer MBC, a condition where breast cancer has spread to other parts of the body. The study focuses on developing a comprehensive questionnaire module to better assess quality of life issues specifically experienced by women with MBC. This new tool will be used alongside the existing EORTC QLQ-C30 questionnaire to provide more detailed and patient-centered measurements. Participants in this observational study will be interviewed across several European centers to guide the development of the questionnaire. Women with MBC, including those with brain metastases without major cognitive impairment, who have received or are receiving various treatments such as chemotherapy, hormone therapy, targeted agents, radiotherapy, or combinations, will help shape the questionnaire content. The study does not involve drug treatments or interventions but gathers detailed patient input through interviews. During the study, researchers will assess the quality of life of female participants with metastatic breast cancer over one month using the new questionnaire module. Patients must be able to understand the language of the questionnaire and provide informed consent. The University of Leeds leads this project, which aims to address the unmet need for specific tools to evaluate HRQOL in this patient group. The study is expected to complete in May 2029.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining gedatolisib with palbociclib and endocrine therapy compared to endocrine therapy with ribociclib for treating adults with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase 3, open-label, randomized clinical trial focuses on patients who are either endocrine-resistant or endocrine-sensitive based on their cancer progression and prior treatments. Participants will be assigned based on endocrine sensitivity status to one of two studies. Study 1 includes patients with endocrine-resistant cancer receiving either gedatolisib plus palbociclib and fulvestrant or ribociclib with fulvestrant. Study 2 includes endocrine-sensitive patients treated with gedatolisib plus palbociclib and letrozole or ribociclib plus letrozole. Gedatolisib is given intravenously once weekly for three weeks followed by a week off. Palbociclib and ribociclib are taken orally on days 1 to 21 of each 28-day cycle. Fulvestrant is administered by intramuscular injection every 2 to 4 weeks, while letrozole is taken orally daily. Throughout the study, participants undergo regular assessments including scans and laboratory tests to monitor disease progression and safety. Researchers measure outcomes such as progression-free survival, overall survival, response rates, duration and time to response, clinical benefits, quality of life, and adverse events over approximately 48 months. The trial includes screening to confirm eligibility and ongoing monitoring during and after treatment to evaluate the treatments effects and safety.